← Back to Search

Serine Protease Inhibitor

Camostat for Coronavirus (COPPS Trial)

Phase 2
Waitlist Available
Led By Chaitan Khosla, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. Outpatient setting
Age ≥ 18 years and ≤ 80 years at the time of the assessment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28
Awards & highlights

COPPS Trial Summary

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol

Eligible Conditions
  • Coronavirus

COPPS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

COPPS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
For the Viral Domain: Change in Viral Shedding
Secondary outcome measures
For Clinical Domain: Time-to-sustained-resolution
Indicator Participant Has Developed Antibodies to SARS-CoV-2
Indicator Participant Has a Negative SARS-CoV2 RT-PCR Test
+4 more

Side effects data

From 2023 Phase 2 & 3 trial • 4044 Patients • NCT04518410
10%
Blood glucose increased
6%
Blood creatinine increased
4%
Fatigue
3%
Cough
3%
Pyrexia
2%
Alanine aminotransferase increased
2%
Dyspnoea
2%
Chills
2%
Nausea
2%
Diarrhoea
2%
Arthralgia
2%
Headache
2%
COVID-19 pneumonia
2%
Pain
2%
Hypertension
2%
Rhinorrhoea
2%
Nasal obstruction
2%
Hyperglycaemia
1%
C-reactive protein increased
1%
Aspartate aminotransferase increased
1%
Blood albumin decreased
1%
Insomnia
1%
Haematocrit decreased
1%
Protein total decreased
1%
Acute kidney injury
1%
Fibrin D dimer increased
1%
Alopecia
1%
Blood urea increased
1%
Blood potassium increased
1%
Blood calcium decreased
1%
Dehydration
1%
Haemoglobin decreased
1%
Red blood cell sedimentation rate increased
1%
Oropharyngeal pain
1%
Serum ferritin increased
1%
Blood sodium decreased
1%
Dizziness
1%
White blood cell count increased
1%
Lymphocyte count decreased
1%
White blood cell count decreased
1%
Acute myocardial infarction
100%
80%
60%
40%
20%
0%
Study treatment Arm
Casirivimab and Imdevimab (Phase 3) OMICRON Population
SAB-185 (Low Dose) (Phase 3) Non-OMICRON Population
Bamlanivimab 700mg (Phase 2)
SAB-185 (Low Dose) Pooled Placebo (Phase 2)
Bamlanivimab 7000 mg (Phase 2)
AZD7442 (IV) (Phase 2)
Bamlanivimab 700mg (Phase 3)
BRII-196+BRII-198 (Pooled Phase 2/3)
BRII-196+BRII-198 Placebo (Pooled Phase 2/3)
AZD7442 (IV) Pooled Placebo (Phase 2)
Camostat (Phase 2)
Camostat Pooled Placebo (Phase 2)
AZD7442 (IM) (Phase 2)
SAB-185 (High Dose) (Phase 2)
AZD7442 (IM) Pooled Placebo (Phase 2)
SNG001 (Phase 2)
Bamlanivimab 7000mg Placebo (Phase 2)
Bamlanivimab 700mg Placebo (Phase 2)
SNG001 Pooled Placebo (Phase 2)
SAB-185 (Low Dose) (Phase 2)
SAB-185 (Low Dose) (Phase 3) OMICRON Population
Casirivimab and Imdevimab (Phase 3) Non-OMICRON Population
SAB-185 (High Dose) Pooled Placebo (Phase 2)
BMS 986414+BMS 986413 Pooled Placebo (Phase 2)
BMS 986414+BMS 986413 (Phase 2)

COPPS Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CamostatExperimental Treatment1 Intervention
Participants are randomized to receive camostat for 10 days.
Group II: Matching PlaceboPlacebo Group1 Intervention
Participants are randomized to receive placebo to match camostat for 10 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Camostat
2021
Completed Phase 3
~4170

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,383 Previous Clinical Trials
17,333,802 Total Patients Enrolled
Chaitan Khosla, PhDPrincipal InvestigatorStanford University
1 Previous Clinical Trials
122 Total Patients Enrolled
Julie Parsonnet, MDPrincipal InvestigatorStanford University
3 Previous Clinical Trials
2,598 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Contemporary Clinical TrialsJournal
The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study Design of a Multi-center Pragmatic Platform Trial
Bunning, Bryan, Haley Hedlin, Natasha Purington, Vandana Sundaram, Kristopher Kapphahn, Yingjie Weng, Kristen Cunanan, et al.. 2021. “The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study Design of a Multi-center Pragmatic Platform Trial”. Contemporary Clinical Trials. Elsevier BV. doi:10.1016/j.cct.2021.106509.
clinicaltrials.govStudy
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol
2021. "COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04662073.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top